Josie Hayes1, Yao Yu2, Llewellyn E Jalbert3, Tali Mazor1, Lindsey E Jones1, Matthew D Wood4, Kyle M Walsh5, Henrik Bengtsson6,7, Chibo Hong1, Stefan Oberndorfer8, Thomas Roetzer9, Ivan V Smirnov1, Jennifer L Clarke1,10,11, Manish K Aghi1, Susan M Chang1,10, Sarah J Nelson3,12, Adelheid Woehrer9, Joanna J Phillips1,4, David A Solomon4, Joseph F Costello1. 1. Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA. 2. Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA. 3. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA. 4. Division of Neuropathology, Department of Pathology, University of California San Francisco, San Francisco, California, USA. 5. Division of Neuroepidemiology, Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA. 6. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA. 7. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA. 8. Department of Neurology, University Hospital of St Poelten, St Poelten, Austria. 9. Institute of Neurology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 10. UCSF Brain Tumor Center, Division of Neuro-Oncology, Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA. 11. Department of Neurology, University of California San Francisco, San Francisco, California, USA. 12. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Abstract
Background: Rare multicentric lower-grade gliomas (LGGs) represent a unique opportunity to study the heterogeneity among distinct tumor foci in a single patient and to infer their origins and parallel patterns of evolution. Methods: In this study, we integrate clinical features, histology, and immunohistochemistry for 4 patients with multicentric LGG, arising both synchronously and metachronously. For 3 patients we analyze the phylogeny of the lesions using exome sequencing, including one case with a total of 8 samples from the 2 lesions. Results: One patient was diagnosed with multicentric isocitrate dehydrogenase 1 (IDH1) mutated diffuse astrocytomas harboring distinct IDH1 mutations, R132H and R132C; the latter mutation has been associated with Li-Fraumeni syndrome, which was subsequently confirmed in the patient's germline DNA and shown in additional cases with The Cancer Genome Atlas data. In another patient, phylogenetic analysis of synchronously arising grade II and grade III diffuse astrocytomas demonstrated a single shared mutation, IDH1 R132H, and revealed convergent evolution via non-overlapping mutations in ATRX and TP53. In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second. Conclusions: Each tumor in multicentric LGG cases may arise independently or may diverge very early in their development, presenting as genetically and histologically distinct tumors. Comprehensive sampling of these lesions can therefore significantly alter diagnosis and management. Additionally, somatic IDH1 R132C mutation in either multicentric or solitary LGG identifies unsuspected germline TP53 mutation, validating the limited number of published cases.
Background: Rare multicentric lower-grade gliomas (LGGs) represent a unique opportunity to study the heterogeneity among distinct tumor foci in a single patient and to infer their origins and parallel patterns of evolution. Methods: In this study, we integrate clinical features, histology, and immunohistochemistry for 4 patients with multicentric LGG, arising both synchronously and metachronously. For 3 patients we analyze the phylogeny of the lesions using exome sequencing, including one case with a total of 8 samples from the 2 lesions. Results: One patient was diagnosed with multicentric isocitrate dehydrogenase 1 (IDH1) mutated diffuse astrocytomas harboring distinct IDH1 mutations, R132H and R132C; the latter mutation has been associated with Li-Fraumeni syndrome, which was subsequently confirmed in the patient's germline DNA and shown in additional cases with The Cancer Genome Atlas data. In another patient, phylogenetic analysis of synchronously arising grade II and grade III diffuse astrocytomas demonstrated a single shared mutation, IDH1R132H, and revealed convergent evolution via non-overlapping mutations in ATRX and TP53. In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second. Conclusions: Each tumor in multicentric LGG cases may arise independently or may diverge very early in their development, presenting as genetically and histologically distinct tumors. Comprehensive sampling of these lesions can therefore significantly alter diagnosis and management. Additionally, somatic IDH1R132C mutation in either multicentric or solitary LGG identifies unsuspected germline TP53 mutation, validating the limited number of published cases.
Authors: Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello Journal: Science Date: 2013-12-12 Impact factor: 47.728
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: A P Kyritsis; M L Bondy; M Xiao; E L Berman; J E Cunningham; P S Lee; V A Levin; H Saya Journal: J Natl Cancer Inst Date: 1994-03-02 Impact factor: 13.506
Authors: Han Fang; Yiyang Wu; Giuseppe Narzisi; Jason A O'Rawe; Laura T Jimenez Barrón; Julie Rosenbaum; Michael Ronemus; Ivan Iossifov; Michael C Schatz; Gholson J Lyon Journal: Genome Med Date: 2014-10-28 Impact factor: 11.117
Authors: F Favero; T Joshi; A M Marquard; N J Birkbak; M Krzystanek; Q Li; Z Szallasi; A C Eklund Journal: Ann Oncol Date: 2014-10-15 Impact factor: 32.976
Authors: Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: Ming Bai; Xiaolong Wang; Huixue Zhang; Jianjian Wang; Gaysina Lyaysan; Si Xu; Kuo Tian; Tianfeng Wang; Jie Li; Na Wang; Xiaoyu Lu; Xiaoming Zhang; Lihua Wang Journal: Biomed Res Int Date: 2022-04-18 Impact factor: 3.246
Authors: Emily A Sloan; Stephanie Hilz; Rohit Gupta; Cathryn Cadwell; Biswarathan Ramani; Jeffrey Hofmann; Cassie N Kline; Anu Banerjee; Alyssa Reddy; Nancy Ann Oberheim Bush; Susan Chang; Steve Braunstein; Edward F Chang; Corey Raffel; Nalin Gupta; Peter P Sun; John Y H Kim; Gregory Moes; Elizabeth Alva; Rong Li; Carol S Bruggers; Mouied Alashari; Cynthia Wetmore; Shipra Garg; Megan Dishop; Jessica Van Ziffle; Courtney Onodera; Patrick Devine; James P Grenert; Julieann C Lee; Joanna J Phillips; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Mitchel S Berger; Joseph F Costello; Arie Perry; David A Solomon Journal: Acta Neuropathol Date: 2020-03-10 Impact factor: 15.887
Authors: Alexander H C W Agopyan-Miu; Matei A Banu; Michael L Miller; Christopher Troy; Gunnar Hargus; Peter Canoll; Tony J C Wang; Neil Feldstein; Aya Haggiagi; Guy M McKhann Journal: Acta Neuropathol Commun Date: 2021-09-29 Impact factor: 7.801